{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:30:51Z","timestamp":1787776251939,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41417-026-01071-2","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:38:59Z","timestamp":1786606739000},"page":"1081-1091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer"],"prefix":"10.1038","volume":"33","author":[{"given":"Xin","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-3791","authenticated-orcid":false,"given":"Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1071_CR1","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"1071_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1071_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1158\/2159-8290.CD-24-0393","volume":"15","author":"JE Medina","year":"2025","unstructured":"Medina JE, Annapragada AV, Lof P, Short S, Bartolomucci AL, Mathios D, et al. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer Discov. 2025;15:105\u201318.","journal-title":"Cancer Discov"},{"key":"1071_CR4","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","volume":"8","author":"A Chandra","year":"2019","unstructured":"Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8:7018\u201331.","journal-title":"Cancer Med"},{"key":"1071_CR5","doi-asserted-by":"crossref","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22:6532.","DOI":"10.3390\/ijms22126532"},{"key":"1071_CR6","doi-asserted-by":"crossref","unstructured":"Hilliard TS, Kowalski B, Iwamoto K, Agadi EA, Liu Y, Yang J, et al. Host mesothelin expression increases ovarian cancer metastasis in the peritoneal microenvironment. Int J Mol Sci. 2021;22:12443.","DOI":"10.3390\/ijms222212443"},{"key":"1071_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/PAI.0000000000001097","volume":"31","author":"S Weidemann","year":"2023","unstructured":"Weidemann S, Gorbokon N, Lennartz M, Hube-Magg C, Fraune C, Bernreuther C, et al. High homogeneity of mesothelin expression in primary and metastatic ovarian cancer. Appl Immunohistochem Mol Morphol. 2023;31:77\u201383.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1071_CR8","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190\u20138.","journal-title":"J Biol Chem"},{"key":"1071_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-106","volume":"10","author":"U Bharadwaj","year":"2011","unstructured":"Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression. Mol Cancer. 2011;10:106.","journal-title":"Mol Cancer"},{"key":"1071_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.","journal-title":"Mol Cancer"},{"key":"1071_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","volume":"39","author":"Y Hu","year":"2018","unstructured":"Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharm Sin. 2018;39:167\u201376.","journal-title":"Acta Pharm Sin"},{"key":"1071_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105695","volume":"74","author":"L Wang","year":"2019","unstructured":"Wang L, Dou M, Ma Q, Yao R, Liu J. Chimeric antigen receptor (CAR)-modified NK cells against cancer: opportunities and challenges. Int Immunopharmacol. 2019;74:105695.","journal-title":"Int Immunopharmacol"},{"key":"1071_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"1071_CR14","doi-asserted-by":"crossref","unstructured":"Raja R, Wu C, Bassoy EY, Rubino TE, Jr., Utagawa EC, Magtibay PM, et al. PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling. J Immunother Cancer. 2022;10:e005026.","DOI":"10.1136\/jitc-2022-005026"},{"key":"1071_CR15","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.7150\/ijbs.88539","volume":"20","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian H, Yang S, Liu M, He J, et al. NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer. Int J Biol Sci. 2024;20:1578\u2013601.","journal-title":"Int J Biol Sci"},{"key":"1071_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039969","volume":"13","author":"SK Nikkhoi","year":"2022","unstructured":"Nikkhoi SK, Li G, Eleya S, Yang G, Vandavasi VG, Hatefi A. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. Front Immunol. 2022;13:1039969.","journal-title":"Front Immunol"},{"key":"1071_CR17","doi-asserted-by":"crossref","unstructured":"Khoshtinat Nikkhoi S, Yang G, Owji H, Grizotte-Lake M, Cohen RI, Gil Gonzalez L, et al. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice. J Immunother Cancer. 2024;12:e008295.","DOI":"10.1136\/jitc-2023-008295"},{"key":"1071_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13727","volume":"57","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang M, Shen X, Xia C, Hu F, Huang D, et al. Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals. Cell Prolif. 2024;57:e13727.","journal-title":"Cell Prolif"},{"key":"1071_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41580-020-00313-x","volume":"22","author":"AJ Covarrubias","year":"2021","unstructured":"Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1071_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s13668-023-00475-y","volume":"12","author":"GFS Alegre","year":"2023","unstructured":"Alegre GFS, Pastore GM. NAD+\u2009Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Curr Nutr Rep. 2023;12:445\u201364.","journal-title":"Curr Nutr Rep"},{"key":"1071_CR21","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s42255-020-00298-z","volume":"2","author":"CCS Chini","year":"2020","unstructured":"Chini CCS, Peclat TR, Warner GM, Kashyap S, Espindola-Netto JM, de Oliveira GC, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD(+) and NMN levels. Nat Metab. 2020;2:1284\u2013304.","journal-title":"Nat Metab"},{"key":"1071_CR22","doi-asserted-by":"crossref","unstructured":"Cao AP, Wang YY, Shen YY, Liu YH, Liu JY, Wang Y, et al. Nicotinamide suppresses hyperactivation of dendritic cells to control autoimmune disease through PARP dependent signaling. Nutrients. 2024;16:2665.","DOI":"10.3390\/nu16162665"},{"key":"1071_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104877","volume":"98","author":"Y Mo","year":"2023","unstructured":"Mo Y, Yue M, Yim LY, Zhou R, Yu C, Peng Q, et al. Nicotinamide mononucleotide impacts HIV-1 infection by modulating immune activation in T lymphocytes and humanized mice. EBioMedicine. 2023;98:104877.","journal-title":"EBioMedicine"},{"key":"1071_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/hep.32658","volume":"78","author":"X Guo","year":"2023","unstructured":"Guo X, Tan S, Wang T, Sun R, Li S, Tian P, et al. NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. Hepatology. 2023;78:468\u201385.","journal-title":"Hepatology"},{"key":"1071_CR25","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH, Gladney WL, Lacey SF, Torigian DA, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27:1919\u201329.","journal-title":"Mol Ther"},{"key":"1071_CR26","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1158\/2326-6066.CIR-25-0174","volume":"13","author":"V Duhan","year":"2025","unstructured":"Duhan V, Gomez MR, Le TT, Rana S, Chen YE. FcR\u03b3-dependent NK cell licensing through CD244 promotes antitumor immunity. Cancer Immunol Res. 2025;13:2075\u201392.","journal-title":"Cancer Immunol Res"},{"key":"1071_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70078","volume":"4","author":"S Chen","year":"2025","unstructured":"Chen S. fastp 1.0: an ultra-fast all-round tool for FASTQ data quality control and preprocessing. Imeta. 2025;4:e70078.","journal-title":"Imeta"},{"key":"1071_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907\u201315.","journal-title":"Nat Biotechnol"},{"key":"1071_CR29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"1071_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1071_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284\u20137.","journal-title":"Omics"},{"key":"1071_CR32","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21:1089\u2013108.","journal-title":"Cell Mol Immunol"},{"key":"1071_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41590-024-01828-7","volume":"25","author":"ACY Chen","year":"2024","unstructured":"Chen ACY, Jaiswal S, Martinez D, Yerinde C, Ji K, Miranda V, et al. The aged tumor microenvironment limits T cell control of cancer. Nat Immunol. 2024;25:1033\u201345.","journal-title":"Nat Immunol"},{"key":"1071_CR34","doi-asserted-by":"crossref","unstructured":"Yang M, Wang B, Hou W, Zeng H, He W, Zhang XK, et al. NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. J Immunother Cancer. 2024;12:e009281.","DOI":"10.1136\/jitc-2024-009281"},{"key":"1071_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02664-1","volume":"22","author":"Q Xu","year":"2022","unstructured":"Xu Q, Liu X, Mohseni G, Hao X, Ren Y, Xu Y, et al. Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. Cancer Cell Int. 2022;22:242.","journal-title":"Cancer Cell Int"},{"key":"1071_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109516","volume":"36","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang F, Wang L, Qiu S, Yao Y, Yan C, et al. NAD(+) supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell Rep. 2021;36:109516.","journal-title":"Cell Rep"},{"key":"1071_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6997","volume":"9","author":"L Li","year":"2023","unstructured":"Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023;9:eadd6997.","journal-title":"Sci Adv"},{"key":"1071_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.it.2004.12.006","volume":"26","author":"D Sancho","year":"2005","unstructured":"Sancho D, G\u00f3mez M, S\u00e1nchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005;26:136\u201340.","journal-title":"Trends Immunol"},{"key":"1071_CR39","doi-asserted-by":"crossref","unstructured":"Arellano-Ballestero H, Zubiak A, Dally C, Orchard K, Alrubayyi A, Charalambous X, et al. Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy. J Immunother Cancer. 2024;12:e008717.","DOI":"10.1136\/jitc-2023-008717"},{"key":"1071_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn0881","volume":"10","author":"M Tarannum","year":"2024","unstructured":"Tarannum M, Dinh K, Vergara J, Birch G, Abdulhamid YZ, Kaplan IE, et al. CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer. Sci Adv. 2024;10:eadn0881.","journal-title":"Sci Adv"},{"key":"1071_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19:120.","journal-title":"Mol Cancer"},{"key":"1071_CR42","doi-asserted-by":"crossref","unstructured":"Eitler J, Wotschel N, Miller N, Boissel L, Klingemann HG, Wels W, et al. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting. J Immunother Cancer. 2021;9:e001334.","DOI":"10.1136\/jitc-2020-001334"},{"key":"1071_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1308143","volume":"14","author":"Z Fan","year":"2023","unstructured":"Fan Z, Han D, Fan X, Zhao L. Ovarian cancer treatment and natural killer cell-based immunotherapy. Front Immunol. 2023;14:1308143.","journal-title":"Front Immunol"},{"key":"1071_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-020-2741-7","volume":"588","author":"TS Luongo","year":"2020","unstructured":"Luongo TS, Eller JM, Lu MJ, Niere M, Raith F, Perry C, et al. SLC25A51 is a mammalian mitochondrial NAD(+) transporter. Nature. 2020;588:174\u20139.","journal-title":"Nature"},{"key":"1071_CR45","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.dnarep.2004.06.002","volume":"3","author":"A Huber","year":"2004","unstructured":"Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair. 2004;3:1103\u20138.","journal-title":"DNA Repair"},{"key":"1071_CR46","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1071_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113395","volume":"153","author":"W Li","year":"2022","unstructured":"Li W, Liang L, Liao Q, Li Y, Zhou Y. CD38: an important regulator of T cell function. Biomed Pharmacother. 2022;153:113395.","journal-title":"Biomed Pharmacother"},{"key":"1071_CR48","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","volume":"10","author":"KA Hogan","year":"2019","unstructured":"Hogan KA, Chini CCS, Chini EN. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10:1187.","journal-title":"Front Immunol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01071-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:02:50Z","timestamp":1787774570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01071-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01071-2","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Peripheral blood from healthy donors were procured under ethical compliance for CAR-NK cell generation. All biological materials were obtained from Shanghai Junxing Biotechnology Co., Ltd. (Shanghai, China), a licensed provider certified by the National Health Commission of China. This study protocol received full ethical approval from the Ethics Committee of Jingkai Hospital (Changsha, China) (Approval No. JH-WBC-20230417). Prior to sample collection, written informed consent was obtained from all participating donors in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}